GNTA
Genenta Science·NASDAQ
--
--(--)
--
--(--)
GNTA fundamentals
During FY 2025, Genenta Science (GNTA) reported revenue of --, a YoY change of 0.00%. Net income was -7.66M, a YoY change of 16.93%. Click to view the full income statement and explore the company's earnings performance.
Income Statement
FY,2019 | H1,2020 | FY,2020 | H1,2021 | FY,2021 | H1,2022 | FY,2022 | H1,2023 | FY,2023 | H1,2024 | FY,2024 | H1,2025 | FY,2025 | TTM |
|---|
Start Date | Jan 1, 2019 | Jan 1, 2020 | Jan 1, 2020 | Jan 1, 2021 | Jan 1, 2021 | Jan 1, 2022 | Jan 1, 2022 | Jan 1, 2023 | Jan 1, 2023 | Jan 1, 2024 | Jan 1, 2024 | Jan 1, 2025 | Jan 1, 2025 | -- |
End Date | Dec 31, 2019 | Jun 30, 2020 | Dec 31, 2020 | Jun 30, 2021 | Dec 31, 2021 | Jun 30, 2022 | Dec 31, 2022 | Jun 30, 2023 | Dec 31, 2023 | Jun 30, 2024 | Dec 31, 2024 | Jun 30, 2025 | Dec 31, 2025 | -- |
Fiscal Year-End | Dec 31 | Dec 31 | Dec 31 | Dec 31 | Dec 31 | Dec 31 | Dec 31 | Dec 31 | Dec 31 | Dec 31 | Dec 31 | Dec 31 | Dec 31 | -- |
Operating Expenses | 5.19M -- | 2.78M -- | 6.84M +31.68% | 4.79M +72.03% | 6.44M -5.85% | 4.35M -9.18% | 11.81M +83.55% | 7.43M +70.75% | 12.98M +9.85% | 4.84M -34.83% | 10.11M -22.13% | 3.98M -17.72% | 7.75M -23.32% | 7.75M -- |
Selling, General and Administrative Expenses | 1.03M -- | 454.97K -- | 1.10M +6.60% | 997.88K +119.33% | 2.60M +135.69% | 2.63M +163.70% | 6.10M +134.80% | 3.14M +19.45% | 5.82M -4.69% | 2.65M -15.56% | 5.13M -11.89% | 2.27M -14.49% | 4.58M -10.60% | 4.58M -- |
General and Administrative Expenses | -- -- | -- -- | 1.10M -- | -- -- | 2.60M +135.69% | -- -- | 6.10M +134.80% | 3.14M -- | 5.82M -4.69% | 2.65M -15.56% | 5.13M -11.89% | 2.27M -14.49% | 4.58M -10.60% | 4.58M -- |
Research and Development Expenses | 4.16M -- | 2.33M -- | 5.73M +37.92% | 3.79M +62.79% | 3.84M -33.07% | 1.72M -54.69% | 5.71M +48.83% | 4.28M +149.35% | 7.16M +25.39% | 2.19M -48.97% | 4.98M -30.44% | 1.71M -21.65% | 3.17M -36.41% | 3.17M -- |
Operating Income | -5.19M -- | -2.78M -- | -6.84M -31.68% | -4.79M -72.03% | -6.44M +5.85% | -4.35M +9.18% | -11.81M -83.55% | -7.43M -70.75% | -12.98M -9.85% | -4.84M +34.83% | -10.11M +22.13% | -3.98M +17.72% | -7.75M +23.32% | -7.75M -- |
Non-Operating Income (Loss) | 30.06K -- | -2.57K -- | -2.19K -107.27% | -7.62K -196.15% | 178.76K +8274.69% | 2.14M +28149.87% | 2.75M +1435.80% | 44.72K -97.91% | 96.78K -96.47% | 513.98K +1049.40% | 881.71K +811.07% | -521.99K -201.56% | 86.74K -90.16% | 86.74K -- |
Gain (Loss) on Foreign Currency Exchange | -- -- | -- -- | 0 -- | -- -- | 0 -- | -- -- | 2.45M -- | -166.03K -- | -239.92K -109.81% | 164.73K +199.22% | 249.45K +203.97% | -709.58K -530.77% | -640.85K -356.90% | -640.85K -- |
Other Non-Operating Income (Loss) | 40.79K -- | -2.57K -- | 7.30K -82.11% | -7.62K -196.15% | 192.02K +2531.67% | 2.14M +28149.87% | 259.48K +35.14% | 125.57K -94.13% | -5.39K -102.08% | 193.63K +54.20% | 548.27K +10266.94% | 10.34K -94.66% | 13.44K -97.55% | 13.44K -- |
Net Interest Expense | 10.72K -- | -- -- | 9.48K -11.57% | -- -- | 13.26K +39.83% | -- -- | -39.57K -398.39% | -85.17K -- | -342.10K -764.61% | -155.62K -82.71% | -83.99K +75.45% | -177.26K -13.90% | -714.14K -750.29% | -714.14K -- |
Interest Expense | 10.72K -- | -- -- | -- -- | -- -- | -- -- | -- -- | -- -- | -- -- | -- -- | -- -- | -- -- | -- -- | -- -- | -- -- |
Interest Income | -- -- | -- -- | -- -- | -- -- | -- -- | -- -- | -- -- | 85.17K -- | -- -- | 155.62K +82.71% | -- -- | 177.26K +13.90% | -- -- | -- -- |
Pretax Income From Continuing Operations | -5.16M -- | -2.79M -- | -6.84M -32.49% | -4.80M -72.15% | -6.26M +8.49% | -2.21M +53.89% | -9.07M -44.92% | -7.38M -233.78% | -12.88M -42.04% | -4.33M +41.40% | -9.23M +28.39% | -4.50M -4.12% | -7.66M +16.93% | -7.66M -- |
Income Tax Expense | -- -- | -- -- | -- -- | -- -- | -- -- | -- -- | -- -- | -- -- | 0 -- | 0 -- | 0 -- | 0 -- | 0 -- | -- -- |
Net Income | -5.16M -- | -2.79M -- | -6.84M -32.49% | -4.80M -72.15% | -6.26M +8.49% | -2.21M +53.89% | -9.07M -44.92% | -7.38M -233.78% | -12.88M -42.04% | -4.33M +41.40% | -9.23M +28.39% | -4.50M -4.12% | -7.66M +16.93% | -7.66M -- |
Net Income Attributable to Owners of the Company | -5.16M -- | -2.79M -- | -6.84M -32.49% | -4.80M -72.15% | -6.26M +8.49% | -2.21M +53.89% | -9.07M -44.92% | -7.38M -233.78% | -12.88M -42.04% | -4.33M +41.40% | -9.23M +28.39% | -4.50M -4.12% | -7.66M +16.93% | -7.66M -- |
Net Income Attributable to Common Stockholders | -5.16M -- | -2.79M -- | -6.84M -32.49% | -4.80M -72.15% | -6.26M +8.49% | -2.21M +53.89% | -9.07M -44.92% | -7.38M -233.78% | -12.88M -42.04% | -4.33M +41.40% | -9.23M +28.39% | -4.50M -4.12% | -7.66M +16.93% | -7.66M -- |
Other Comprehensive Income | -- -- | -- -- | -- -- | -- -- | -- -- | -- -- | -- -- | -- -- | 220.28K -- | -86.08K -- | -147.19K -166.82% | 51.31K +159.61% | 91.03K +161.85% | 91.03K -- |
Total Comprehensive Income | -5.16M -- | -2.79M -- | -6.84M -32.49% | -4.80M -72.15% | -6.26M +8.49% | -2.21M +53.89% | -9.07M -44.92% | -7.38M -233.78% | -12.66M -39.61% | -4.41M +40.23% | -9.37M +25.98% | -4.45M -0.93% | -7.57M +19.21% | -7.57M -- |
Total Comprehensive Income Attributable to Owners of the Company | -5.16M -- | -2.79M -- | -6.84M -32.49% | -4.80M -72.15% | -6.26M +8.49% | -2.21M +53.89% | -9.07M -44.92% | -7.38M -233.78% | -12.66M -39.61% | -4.41M +40.23% | -9.37M +25.98% | -4.45M -0.93% | -7.57M +19.21% | -7.57M -- |
Basic EPS | -- -- | -- -- | -- -- | -0.32 -- | -0.42 -- | -0.13 +59.38% | -0.5 -19.05% | -0.4 -207.69% | -0.71 -42.00% | -0.24 +40.00% | -0.51 +28.17% | -0.24 -- | -0.39 +23.53% | -0.39 -- |
Basic EPS from Continuing Operations | -- -- | -- -- | 0 -- | -- -- | -0.42 -- | -- -- | -0.5 -19.05% | -0.4 -- | -0.71 -42.00% | -0.24 +40.00% | -0.51 +28.17% | -0.24 -- | -0.39 +23.53% | -0.39 -- |
Diluted EPS | -- -- | -- -- | -- -- | -- -- | -0.42 -- | -- -- | -0.5 -19.05% | -0.4 -- | -- -- | -0.24 +40.00% | -- -- | -0.24 -- | -- -- | -- -- |
Diluted EPS from Continuing Operations | -- -- | -- -- | 0 -- | -- -- | -0.42 -- | -- -- | -0.5 -19.05% | -0.4 -- | -- -- | -0.24 +40.00% | -- -- | -0.24 -- | -- -- | -- -- |
You can ask Aime
What is Genenta Science's latest dividend and current dividend yield?What does Genenta Science do and what are its main business segments?What is the revenue and EPS growth rate for Genenta Science year over year?What is Genenta Science's gross profit margin?What factors drove the changes in Genenta Science's revenue and profit?What guidance did Genenta Science's management provide for the next earnings period?Did Genenta Science beat or miss consensus estimates last quarter?What is the market's earnings forecast for Genenta Science next quarter?
ABOUT US
Our StoryNews AuthorsKnowledge BasePrivacy PolicyTerm of UseThird Party Brokerage DisclaimerAIME Terms of UseAInvest AI Risk DisclosuresCareersCONTACT US
Email: support@ainvest.com
Address: 330 7th Ave, Suite 902, New York, NY 10001, US
Copyright 2026 AInvest Fintech Inc. All rights reserved.
